← All organizations
Highest phase reached
Phase 2
First clinical trial
Apr 1, 2005Last known activity
Oct 31, 2025
Timeline
1990s
- Jan 1, 1995
Sangamo BioSciences— Founded
2010s
- Aug 1, 2013
Ceregene— Acquired
Drugs by trial phase (17 distinct, 25 trials)
Phase 2 (10 own, 2 via acquisition)
Phase 1 (5 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Alzheimer Disease
- Amyotrophic Lateral Sclerosis
- beta-Thalassemia
- Communicable Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Diabetes Mellitus, Type 2
- Diabetic Neuropathies
- Fabry Disease
- Hemophilia A
- Hemophilia B
- HIV Infections
- Infections
- Motor Neuron Disease
- Mucopolysaccharidoses
- Mucopolysaccharidosis I
- Mucopolysaccharidosis II
- Parkinson Disease
- Peripheral Nervous System Diseases
- Polyneuropathies
- Sclerosis
- Thalassemia
Subsidiaries (1 direct, 1 total across the full acquisition tree)
Recent trials (34)
- NCT06980948Lead sponsorPhase 1/Phase 2Oct 31, 2025
- NCT04817774Lead sponsorPhase 1/Phase 2Mar 17, 2021
- NCT04046224Lead sponsorPhase 1/Phase 2Jul 23, 2019
- NCT04046224Study directorPhase 1/Phase 2Jul 23, 2019
- NCT03432364Study directorPhase 1/Phase 2Mar 29, 2018
- NCT03432364Lead sponsorPhase 1/Phase 2Mar 29, 2018
- NCT03061201Lead sponsorPhase 1/Phase 2Jun 2, 2017
- NCT03061201Study directorPhase 1/Phase 2Jun 2, 2017
- NCT02702115Study directorPhase 1May 1, 2017
- NCT02702115Lead sponsorPhase 1May 1, 2017
- NCT03041324Study directorPhase 1Apr 21, 2017
- NCT03041324Lead sponsorPhase 1Apr 21, 2017
- NCT02695160Study directorPhase 1Jun 1, 2016
- NCT02695160Lead sponsorPhase 1Jun 1, 2016
- NCT02500849CollaboratorPhase 1Jul 1, 2015
Details
- Founded
- Richmond, CA, US Jan 1, 1995
- Last known activity
- Oct 31, 2025